Genomma Lab has announced that the Mexican Federal Commission for the Protection Against Health Risks (COFEPRIS) has granted the Sanitary License which permits the Company's new manufacturing facility to begin operations of the first Solid (pills) and Semisolid (ointments) though its state-of-the-art OTC production lines.
Receiving the Sanitary License represents a key objective in the process of earning the GMP certification (Good Manufacturing Practices), required to sell pharma-grade products to the market.
The Company will now begin the filing process with COFEPRIS to obtain the GMP certificates for Mexico and all markets in which the Company operates. Genomma Lab will also apply for GMP certificates to be granted by the National Regulatory Body of each export market.
Genomma's Lab investment in a 70,000 sqm export-oriented manufacturing facility will generate thousands of direct and indirect jobs while creating value for the Company shareholders.